Anti-platelet drugs find a place virtually in every prescription written by a cardiologist for CAD.No doubt, it sits right on top among the highest prescribed medication in the world. They are used in all forms of CAD/ ACS. It becomes mandatory in post PCI as a stent maintenance protocol.
Cardiologists (at least me) are exhausted with so many studies with these drugs. When we thought we are relaxing for a while, the current issue of circulation release a big meta-analysis with 50,000 patient data.It tries to draw fresh battle lines between the three friendly P2Y12 inhibitors.
- The findings, from the meta-analysis, directly confront the famed study ISAR React 5 (NEJM 2019)which apparently crowned Ticagrelor the superiority cap over prasugrel
- It says Ticagrelor is as good as Prasugrel in any ACS patients.
- I guess this meta-analysis is meant to remove the huge faith cardiologists show towards Prasugrel (Still as on date, Prasu is probably best for stent thrombosis prevention in complex PCIs)
- While the humbled and knocked out clopidogrel still manages to woo, with its low bleeding risk and cost .(Comorbid patients)
- As expected Aspirin, is not even in the fighting ring, just chucked out by the referee for being too smart and threatening the famed heavyweights.(THEMIS brings Ticagrelor even for primary prevention 2020 FDA approved)
What should you believe in?
This meta-analysis or the ISAR React 5? Don’t believe either, Then what shall I do? Maybe, go with your Intuition. (Considering the fact, P2Y12 receptors are more attracted to unidentified wall street ligands, than Adenosine diphosphates)
Let us hope true breakthroughs happen in antiplatelet drugs so that we no longer need to see these boring fights between the same old drugs.